An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
← catalyst calendarNCT07220603 · readout ≤ 896 d
Sponsored by PepGen Inc (industry) · PEPG — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
48estimated
Sites
3
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-23 | actual | When the study began enrolling |
| Primary completion | Jan 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myotonic Dystrophy 1
Intervention
- Drug: PGN-EDODM1
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability as assessed by number of participants with Adverse Events (AEs)
measured Baseline through Week 108
Permalink · PEPG's whole pipeline · Catalyst calendar · Every registered study · What changed